| scholarly article | Q13442814 |
| P50 | author | Hui-Min Neoh | Q56451773 |
| Ilana L. Camargo | Q79142007 | ||
| Keiichi Hiramatsu | Q106083013 | ||
| P2093 | author name string | Minoru Fukuda | |
| Yukiko Watanabe | |||
| Tomonori Ochiai | |||
| Tomomi Hishinuma | |||
| Longzhu Cui | |||
| Mitsutaka Shoji | |||
| Taisuke Isii | |||
| P2860 | cites work | Studies on the mechanism of ristocetin-induced platelet agglutination. Effects of structural modification of ristocetin and vancomycin | Q24595238 |
| Lipid-specific binding of the calcium-dependent antibiotic daptomycin leads to changes in lipid polymorphism of model membranes. | Q31155851 | ||
| Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus | Q31830904 | ||
| DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus. | Q33220466 | ||
| Effect of divalent cations on the structure of the antibiotic daptomycin. | Q46925250 | ||
| Daptomycin: a novel agent for Gram-positive infections. | Q53852746 | ||
| Vancomycin adsorption to Bacillus subtilis cell walls | Q69982951 | ||
| Overexpression of sigma factor, sigma(B), urges Staphylococcus aureus to thicken the cell wall and to resist beta-lactams | Q74630591 | ||
| Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy | Q79922013 | ||
| How bacteraemia is reviewed by medicines licensing authorities in Europe | Q81330455 | ||
| The GraRS regulatory system controls Staphylococcus aureus susceptibility to antimicrobial host defenses. | Q33339694 | ||
| Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides | Q33855582 | ||
| Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vi | Q33981366 | ||
| Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms | Q34045376 | ||
| Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus | Q34073487 | ||
| The emergence and evolution of methicillin-resistant Staphylococcus aureus | Q34094813 | ||
| Status of methods for assessing bacterial cell surface charge properties based on zeta potential measurements | Q34105427 | ||
| In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus | Q34509698 | ||
| Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance | Q34547868 | ||
| Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing | Q34630593 | ||
| Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus | Q34680589 | ||
| Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus | Q34747322 | ||
| Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherap | Q34975155 | ||
| Suppression of methicillin resistance in a mecA-containing pre-methicillin-resistant Staphylococcus aureus strain is caused by the mecI-mediated repression of PBP 2' production | Q35129607 | ||
| Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus | Q35166213 | ||
| Staphylococcus aureus with reduced susceptibility to vancomycin | Q35882353 | ||
| Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. | Q36094925 | ||
| Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding | Q36422686 | ||
| Daptomycin: a review 4 years after first approval | Q36972980 | ||
| NMR structural studies of the antibiotic lipopeptide daptomycin in DHPC micelles. | Q36975076 | ||
| Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype. | Q38360418 | ||
| Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. | Q39474811 | ||
| RNA polymerase inhibitors with activity against rifampin-resistant mutants of Staphylococcus aureus | Q39537295 | ||
| Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus | Q39559116 | ||
| Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence | Q41851810 | ||
| Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin | Q41884192 | ||
| Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. | Q41912284 | ||
| Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin | Q42042890 | ||
| Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem | Q42111612 | ||
| Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus | Q42111665 | ||
| Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. | Q42111733 | ||
| Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus. | Q42112490 | ||
| Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. | Q42112516 | ||
| Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus | Q42119436 | ||
| daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations | Q42197385 | ||
| Staphylococcus aureus strains lacking D-alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice. | Q44074411 | ||
| Resistance to a polyquaternium-1 lens care solution and isoelectric points of Pseudomonas aeruginosa strains | Q44080445 | ||
| Daptomycin. | Q44751135 | ||
| Identification of the first vancomycin intermediate-resistant Staphylococcus aureus (VISA) isolate from a hospital in Portugal | Q44837920 | ||
| Allelic replacement in Staphylococcus aureus with inducible counter-selection. | Q46624193 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| vancomycin | Q424027 | ||
| P304 | page(s) | 5222-5233 | |
| P577 | publication date | 2010-09-13 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus | |
| An RpoB Mutation Confers Dual Heteroresistance to Daptomycin and Vancomycin in Staphylococcus aureus | |||
| P478 | volume | 54 |
| Q42109713 | "Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3. |
| Q30455758 | A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin |
| Q90502080 | A mutation in the glycosyltransferase gene lafB causes daptomycin hypersusceptibility in Enterococcus faecium |
| Q36505583 | A mutation of the RNA polymerase β' subunit (rpoC) confers cephalosporin resistance in Bacillus subtilis. |
| Q34648042 | Additional routes to Staphylococcus aureus daptomycin resistance as revealed by comparative genome sequencing, transcriptional profiling, and phenotypic studies |
| Q40631566 | Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections |
| Q38310639 | Antimicrobial heteroresistance: an emerging field in need of clarity. |
| Q100395098 | Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) |
| Q99630758 | Characterization of methicillin-resistant Staphylococcus aureus through genomics approach |
| Q38394500 | Collateral sensitivity of antibiotic-resistant microbes. |
| Q36964857 | Comparative proteomics-based identification of genes associated with glycopeptide resistance in clinically derived heterogeneous vancomycin-intermediate Staphylococcus aureus strains |
| Q40719288 | Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureus |
| Q59647553 | Comprehensive antibiotic-linked mutation assessment by resistance mutation sequencing (RM-seq) |
| Q37335734 | Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3 |
| Q48505745 | Convergent Evolution Driven by Rifampin Exacerbates the Global Burden of Drug-Resistant Staphylococcus aureus. |
| Q36056622 | Coordinated phenotype switching with large-scale chromosome flip-flop inversion observed in bacteria |
| Q30575519 | Current data and trends on methicillin-resistant Staphylococcus aureus (MRSA) |
| Q26863225 | Cyclic lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteria |
| Q47616115 | Daptomycin |
| Q58609304 | Daptomycin Resistance and Tolerance Due to Loss of Function in Staphylococcus aureus dsp1 and asp23. |
| Q47116570 | Daptomycin Resistance in Clinical MRSA Strains Is Associated with a High Biological Fitness Cost |
| Q34405922 | Daptomycin resistance in enterococci is associated with distinct alterations of cell membrane phospholipid content |
| Q33696380 | Dissecting vancomycin-intermediate resistance in staphylococcus aureus using genome-wide association. |
| Q37824612 | Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient--a review of the literature |
| Q92091420 | Environment Shapes the Accessible Daptomycin Resistance Mechanisms in Enterococcus faecium |
| Q33939055 | Evaluation of Daptomycin Non-Susceptible Staphylococcus aureus for Stability, Population Profiles, mprF Mutations, and Daptomycin Activity |
| Q40602795 | Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model |
| Q41570351 | Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocar |
| Q28477900 | Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR |
| Q90165730 | Evolution of resistance mechanisms and biological characteristics of rifampicin-resistant Staphylococcus aureus strains selected in vitro |
| Q24490083 | Evolution of resistance to a last-resort antibiotic in Staphylococcus aureus via bacterial competition |
| Q34116509 | First case report of vancomycin-intermediate sequence type 72 Staphylococcus aureus with nonsusceptibility to daptomycin |
| Q44704078 | First isolation in Argentina of community-acquired methicillin-resistant Staphylococcus aureus with intermediate susceptibility to vancomycin and nonsusceptibility to daptomycin |
| Q42202739 | Generation of a vancomycin-intermediate Staphylococcus aureus (VISA) strain by two amino acid exchanges in VraS. |
| Q34389310 | Genetic and proteomic characterization of rpoB mutations and their effect on nematicidal activity in Photorhabdus luminescens LN2. |
| Q33876255 | Genetic basis for daptomycin resistance in enterococci |
| Q37643403 | Genome sequence-based discriminator for vancomycin-intermediate Staphylococcus aureus. |
| Q42738785 | Genome-wide analysis captures the determinants of the antibiotic cross-resistance interaction network. |
| Q58716354 | Genomic exploration of sequential clinical isolates reveals a distinctive molecular signature of persistent Staphylococcus aureus bacteraemia |
| Q57823035 | Global spread of three multidrug-resistant lineages of Staphylococcus epidermidis |
| Q35385568 | Heterogeneity of genetic pathways toward daptomycin nonsusceptibility in Staphylococcus aureus determined by adjunctive antibiotics |
| Q35807220 | Heteroresistance to cephalosporins and penicillins in Acinetobacter baumannii |
| Q41855274 | Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus |
| Q36999966 | Improved understanding of factors driving methicillin-resistant Staphylococcus aureus epidemic waves |
| Q40056214 | In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides. |
| Q41862843 | In vivo evolution of antimicrobial resistance in a series of Staphylococcus aureus patient isolates: the entire picture or a cautionary tale? |
| Q37658042 | Large tandem chromosome expansions facilitate niche adaptation during persistent infection with drug-resistant Staphylococcus aureus |
| Q37947249 | MRSA: the first half century |
| Q33613003 | Management of Resistant, Atypical and Culture-negative Periprosthetic Joint Infections after Hip and Knee Arthroplasty |
| Q38942573 | Mechanism of Action and Resistance to Daptomycin in Staphylococcus aureus and Enterococci |
| Q38380412 | Molecular analysis of methicillin-resistant Staphylococcus aureus dissemination among healthcare professionals and/or HIV patients from a tertiary hospital. |
| Q34536929 | Molecular characterization of methicillin-resistant Panton-valentine leukocidin positive staphylococcus aureus clones disseminating in Tunisian hospitals and in the community |
| Q59806009 | Molecular prophage typing of isolates from bovine mastitis |
| Q28480626 | Multiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencing |
| Q38282740 | Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3. |
| Q42110109 | Mutation of RNA polymerase β-subunit gene promotes heterogeneous-to-homogeneous conversion of β-lactam resistance in methicillin-resistant Staphylococcus aureus |
| Q34593241 | Mutations in the primary sigma factor σA and termination factor rho that reduce susceptibility to cell wall antibiotics |
| Q35867495 | Mutations in the β subunit of RNA polymerase alter intrinsic cephalosporin resistance in Enterococci |
| Q40809099 | Phenotypic Modifications in Staphylococcus aureus Cells Exposed to High Concentrations of Vancomycin and Teicoplanin |
| Q38966881 | Potential for adaptation overrides cost of resistance. |
| Q34632683 | Production of capsular polysaccharide does not influence Staphylococcus aureus vancomycin susceptibility |
| Q89500845 | RNA polymerase mutations cause cephalosporin resistance in clinical Neisseria gonorrhoeae isolates |
| Q59805017 | Reconstruction of the Vancomycin-Susceptible Phenotype From a Vancomycin-Intermediate XN108 |
| Q38282693 | Reduction in membrane phosphatidylglycerol content leads to daptomycin resistance in Bacillus subtilis |
| Q41129709 | Research of the heteroresistance of Pseudomonas aeruginosa to imipenem. |
| Q35619094 | Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era |
| Q42772389 | Reversible daptomycin tolerance of adherent staphylococci in an implant infection model |
| Q36081351 | Rifampin Resistance rpoB Alleles or Multicopy Thioredoxin/Thioredoxin Reductase Suppresses the Lethality of Disruption of the Global Stress Regulator spx in Staphylococcus aureus |
| Q36153912 | Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus |
| Q35746096 | Staphylococcus aureus metabolic adaptations during the transition from a daptomycin susceptibility phenotype to a daptomycin nonsusceptibility phenotype. |
| Q36158472 | Stepwise decrease in daptomycin susceptibility in clinical Staphylococcus aureus isolates associated with an initial mutation in rpoB and a compensatory inactivation of the clpX gene |
| Q37683485 | The impact of drug resistance on Mycobacterium tuberculosis physiology: what can we learn from rifampicin? |
| Q34436348 | Transposon library screening for identification of genetic loci participating in intrinsic susceptibility and acquired resistance to antistaphylococcal agents. |
| Q39392178 | Use of bacterial whole-genome sequencing to understand and improve the management of invasive Staphylococcus aureus infections |
| Q92490264 | Using genomics to understand meticillin- and vancomycin-resistant Staphylococcus aureus infections |
| Q95355781 | Vancomycin Resistance in Staphylococcus aureus |
| Q38462842 | Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus - a clinician's guide to the science informing current practice |
| Q37236231 | Vancomycin susceptibility in methicillin-resistant Staphylococcus aureus is mediated by YycHI activation of the WalRK essential two-component regulatory system |
| Q57492422 | as a Prominent Resource of Future Anti-MRSA Drugs |
| Q42110968 | walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus. |
Search more.